Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 19/20 | 0.81 |
| ▸ | KDM5A | P29375 | 1/20 | 0.56 |
| ▸ | KDM5C | P41229 | 1/20 | 0.56 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871685 | 0.94 | PDE9A (0.78) | PDE9A | |
| SCHEMBL20870397 | 0.90 | PDE9A (1.00) | PDE9A | |
| SCHEMBL24203157 | 0.89 | PDE9A (0.75) | PDE9AKDM5AKDM5CKDM5B | |
| SCHEMBL20870137 | 0.88 | PDE9A (1.00) | PDE9A | |
| SCHEMBL20870403 | 0.88 | PDE9A (1.00) | PDE9A | |
| SCHEMBL20870263 | 0.88 | PDE9A (0.83) | PDE9AKDM5AKDM5CKDM5B | |
| SCHEMBL20870609 | 0.87 | PDE9A (0.82) | PDE9A | |
| SCHEMBL20870559 | 0.87 | PDE9A (0.78) | PDE9AKDM5AKDM5CKDM5B | |
| SCHEMBL22871686 | 0.87 | PDE9A (0.85) | PDE9A | |
| SCHEMBL22298231 | 0.86 | PDE9A (0.80) | PDE9AKDM5AKDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434248-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| CN-113956252-A | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-109575016-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| EP-3689876-A1 | PDE9 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200115384-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2020-04-16 | — | — | US | disclosed |
| WO-2019062733-A1 | PDE9 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889591-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | PDE9A 2/4885KDM5A 1199/4885KDM5C 2394/4885 |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE3A, PDE9A, PDE3B | PDE9A 2/4885KDM5A 1199/4885KDM5C 2394/4885 |
| US-11434248-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | PDE9A 2/4885KDM5A 1199/4885KDM5C 2394/4885 |
| US-20200115384-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE3A, PDE9A, PDE3B | PDE9A 2/4885KDM5A 1199/4885KDM5C 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.